-----BEGIN PRIVACY-ENHANCED MESSAGE----- Proc-Type: 2001,MIC-CLEAR Originator-Name: webmaster@www.sec.gov Originator-Key-Asymmetric: MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB MIC-Info: RSA-MD5,RSA, MscoiGSRk/K1v5CmGrDmpbAVESF5Z1k5kkRQXPSQf61cBRJNOkCyYNhESJO7KVFv eo1qnFf2+3sOGhe/al8DxA== 0001036050-99-002505.txt : 19991215 0001036050-99-002505.hdr.sgml : 19991215 ACCESSION NUMBER: 0001036050-99-002505 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 19991214 ITEM INFORMATION: FILED AS OF DATE: 19991214 FILER: COMPANY DATA: COMPANY CONFORMED NAME: CEPHALON INC CENTRAL INDEX KEY: 0000873364 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 232484489 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: SEC FILE NUMBER: 000-19119 FILM NUMBER: 99774399 BUSINESS ADDRESS: STREET 1: 145 BRANDYWINE PKWY CITY: WEST CHESTER STATE: PA ZIP: 19380 BUSINESS PHONE: 6103440200 MAIL ADDRESS: STREET 1: 145 BRANDYWINE PARKWAY CITY: WEST CHESTER STATE: PA ZIP: 19380 8-K 1 FORM 8-K SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 DATE OF REPORT (DATE OF EARLIEST EVENT REPORTED): December 14, 1999 ------------------ Cephalon, Inc. -------------------------------------------------------------------- (Exact name of registrant specified in Charter) Delaware 0-19119 23-2484489 -------------------------------------------------------------------- (State or other (Commission (IRS Employee jurisdiction of File Number) Identification No.) incorporation) 145 Brandywine Parkway West Chester, PA 19380 -------------------------------------------------------------------- (Address of principal executive offices) Zip Code Registrant's telephone, including area code: 610-344-0200 -------------------------------------------------------------------- (Former name and former address, if changed since last report) Item 5. Other Events ------------ The Company received in November 1999, and is responding to, a federal grand jury subpoena in connection with an investigation under the supervision of the Office of Consumer Litigation of the U.S. Department of Justice. The grand jury also issued subpoenas to certain former and current employees of the Company. The Company believes that the investigation relates to the release during the period 1994-96 of some lots of Myotrophin used in clinical trials and related reports filed with the U.S. Food and Drug Administration. The Company has not been identified by the Department of Justice as being a target of the investigation and is cooperating with the inquiry. The Company cannot predict the outcome of the investigation. SIGNATURE --------- Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. CEPHALON, INC. Date: December 14, 1999 By: /s/ J. Kevin Buchi -------------------------------------- J. Kevin Buchi Senior Vice President, Chief Financial Officer -----END PRIVACY-ENHANCED MESSAGE-----